Generic smear campaign earns Merck French fine
This article was originally published in Scrip
Executive Summary
The French competition authority has fined Merck & Co's Schering-Plough business €15.3m for attempting to block from the market a generic version of its opioid addiction drug Subutex (buprenorphine).
You may also be interested in...
French Competition Body Fines Janssen €25m For Delaying Generic Durogesic
Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.
French Competition Body Fines Janssen €25m For Delaying Generic Durogesic
Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.